AFMCP_2016_June_ATX0285


Each day, sessions will begin at 8am and end at 6pm. Healthful snacks will be provided at the mid-morning and mid-afternoon breaks. On Saturday evening, a non-CME session entitled Business and Clinical Strategies for Successful Practice Implementation will be offered from 7:30-9pm.

SATURDAY, MARCH 11 (DAY ONE)


Welcome, Orientation, Background, and Themes
Robert Luby, MD
The spectrum of cognitive impairment represents perhaps the most feared and least successfully treated medical condition of our time. Individuals with cognitive impairment are likely to have variable and protean underlying causes that result from the interaction of genetics and environment. Clinical research has demonstrated meaningful restoration of cognitive function when patients are treated with a multimodal programmatic approach. The Functional Medicine paradigm, with its emphasis on systems biology and the genome/environome dyad, provides a clinical framework for the implementation of successful, individualized therapeutic interventions.  

Cognitive Impairment: Evolution, Pathology, and Physiology
Dale Bredesen, MD
The genomic antecedents that predispose many individuals to cognitive impairment represent favorable evolutionary adaptations to the environment of our earlier ancestors. Building on pre-onsite foundational material delivered to attendees, Dr. Bredesen will explain how the pathophysiology of neurodegeneration represents an adaptive and protective response to three environmental challenges as well as the molecular mechanisms that mediate the processes of cognitive decline.

Gathering Data: Contributors and Clinical Subtypes – Parts 1 & 2
Robert Luby, MD
The therapeutic approach to each individual is determined by the underlying causes and contributors unique to that individual. Dr. Luby will explain how MCI and AD may be distinguished clinically from other causes of dementia and will demonstrate the use of clinical tools to discover how antecedents, triggers, and mediators discovered in the “Gather” step correlate with recognizable, albeit overlapping, clinical subtypes.

Organizing Clinical Data: Mapping Mechanisms on the Matrix
Robert Luby, MD
The Functional Medicine Matrix is an ideal tool for identifying, understanding, and distinguishing the protean underlying contributors to cognitive impairment. Dr. Luby will demonstrate how clinicians may use this tool to determine the relative contributions of each of the “clinical subtypes” in individual patients. 

Telling the Story: Motivation, Adherence, Caretakers, and the Care Team

Mark Menolascino, MD, MS
In any chronic disease, it is important to engage caretakers and a collaborative care team to achieve optimal outcomes. Given the inherent limitations of the patient with cognitive impairment, this assumes even more importance. Dr. Menolascino will offer a variety of options for engaging caretakers and collaborative care teams.

Ordering and Prioritizing Interventions
Robert Luby, MD
Dr. Bredesen’s research concludes that MCI and AD can be successfully treated with a multimodal programmatic approach that is personalized and patient-specific. Dr. Luby will demonstrate the use of clinical tools to identify predictors of success when assessing the patient and the condition and will lay the foundation for the multimodal approach by introducing the concept of physiologic choice points.

Initiating and Tracking Laboratory Evaluations: Rationale by Subtype
Jill Carnahan, MD
The numerous potential underlying contributors to cognitive impairment render it imperative that clinicians be judicious in their selection of laboratory evaluations.  Dr. Carnahan will demonstrate clinical tools to guide clinicians through the decision-making process to achieve both clinically effective and cost effective initial and follow-up laboratory evaluations.

Initiating Lifestyle Interventions, Supplements, and Nutraceuticals
Mark Menolascino, MD, MS
The numerous contributors to cognitive impairment demand a multimodal therapeutic approach. With an emphasis on inflammatory contributors, Dr. Menolascino will explain the rationale for combining lifestyle interventions, supplements, and nutraceuticals in an individualized treatment approach and will introduce point-of-care clinical tools to assist clinical decision-making.


SUNDAY, MARCH 12 (DAY TWO)


Hormonal Contributors: Evaluation and Interventions    
Mark Menolascino, MD, MS
The withdrawal of trophic factors and hormone deficiencies plays significant roles in the development of many cases of cognitive impairment. Dr. Menolascino will introduce tools to guide clinicians through the approach to the clinical recognition, diagnostic evaluation, and therapeutic interventions of this mediator of neurodegeneration.

Infectious and Toxic Contributors: Evaluation and Interventions    

Jill Carnahan, MD
A variety of microbes, biotoxins, and environmental toxins play significant roles in the development of many cases of cognitive impairment. Dr. Carnahan will introduce tools to guide clinicians through the approach to the clinical recognition, diagnostic evaluation, and therapeutic interventions of these mediators of neurodegeneration.

Clinical Applications of the Software
Dale Bredesen, MD
The plethora of potential underlying contributors to cognitive impairment provides the rationale for software programs to guide clinical decision-making. Dr. Bredesen will demonstrate the value of a clinical software program in achieving optimal patient outcomes.   

Initiating and Tracking Diagnostic Evaluations: Neuroimaging
Cyrus Raji, MD, PhD
For patients with cognitive impairment, neuroimaging is often a key evaluation tool for both diagnosis and tracking of progress. Dr. Raji will demonstrate clinical tools to help clinicians distinguish how and when it is most useful, as well as the strengths and limitations of the various neuroimaging modalities. 

Case Studies   
Mark Menolascino, MD, MS
Dale Bredesen, MD
Drs. Menolascino and Bredesen will present case studies demonstrating point-of-care clinical tools and software to clarify and reinforce the concepts and principles of effective clinical approaches to the reversal of cognitive decline.  

Emerging Research, Future Clinical Strategies, and the Clinician Support Program
Dale Bredesen, MD
Dr. Bredesen will describe ongoing and emerging research that will inform future clinical approaches to the reversal of cognitive decline. He will also introduce a “Clinician Support Program” designed to provide ongoing training and support for all clinicians attending this conference.


*Schedule is subject to change

Disclosure text is not available